Patent · US Active

Fibronectin based scaffold domain proteins that bind PCSK9

US9234027B2 · kind B2 · utility

6Cited by

21References

22Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ray Camphausen · Wayland, US
Jonathan Davis · Waltham, US
Sharon Cload · Cambridge, US
Fabienne M. Denhez · Arlington, US
Amna Saeed-Kothe · Dedham, US
Dasa Lipovsek · Pepperell, US
Ching-Hsiung Frederick Lo · Pennington, US
Chee Meng Low · Singapore, SG
Bowman Miao · Nazareth, US
Tracy S. Mitchell · Andover, US
Rex A. Parker · Titusville, US
Ginger Rakestraw · Cambridge, US
Katie A. Russo · Watertown, US
Doree F. Sitkoff · Dresher, US

Key dates

Filing date	Mar 15, 2013
Grant date	Jan 12, 2016
Priority date	—
Expiry date	May 7, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.